Pfizer has paid $47.5 million to reclaim full commercialisation rights to the blood clotting factors ReFacto and BeneFIX in the Nordic region from Swedish Orphan Biovitrum (Sobi), which held co-promotion rights there.
Pfizer told Scrip: "Pfizer and Sobi have simplified their relationship for the commercialisation of ReFacto and BeneFIX in the Nordic Region, with the return of the co-promotion rights
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?